Invivyd, Inc. (IVVD) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

During today's discussion, we will be making forward-looking statements concerning, among other things, our corporate and commercial strategy, our research and development activities, our regulatory plans, certain financial expectations, our future prospects and other statements that are not historical facts. These forward-looking statements are covered within the meaning of the Private Securities Litigation Reform Act and are subject to various risks, assumptions and uncertainties that may change over time and cause our actual results to differ materially from those expressed or implied today. These forward-looking statements speak only as of the date of this call, and NVivid assumes no duty to update such statements. Additional information on the risk factors that could affect NVivid's business can be found in our filings made with the U.S. Securities and Exchange Commission, including our most recent Form 10-K and 10-Q, which are also available on our website. I will now turn the call over to Mark. Thank you, Katie, and good morning, everyone. The third quarter for InVivid marked a turning point in our company's history and, we hope, also marked the beginning of substantial change in how we may prevent COVID for vulnerable Americans in the near future. In the third quarter, in addition to growing our Pemgarda commercial franchise, we received feedback from the U.S. FDA, a fellow of our vaccine alternative antibody, VYD2311, for broad populations that continue to suffer from COVID and who are not adequately served by current COVID vaccines. This feedback and our next steps at InVivid are the result of years of InVivid innovation and dialogue on that innovation with the FDA. By focusing on molecular evolution and by demonstrating the clinical benefits of our medicin...